CYNK-001 Granted Orphan Drug Designation for Treatment of Malignant Gliomas

April 13, 2021

The FDA has granted orphan drug designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the treatment of patients with malignant gliomas.

Breast Cancer Testing May Benefit from the Multi-Omics Approach Over Biomarker Assessment Alone

April 13, 2021

For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.

Lenalidomide Reduces Infection Mortality Rates in COVID-19-Positive Patients With Multiple Myeloma

April 13, 2021

Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.

Telisotuzumab Vedotin Shows Promising Efficacy and Safety Results for c-Met+ NSCLC

April 13, 2021

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.